scispace - formally typeset
F

F. Cattelan

Researcher at University of Genoa

Publications -  7
Citations -  48

F. Cattelan is an academic researcher from University of Genoa. The author has contributed to research in topics: Osteoporosis & Bone mineral. The author has an hindex of 2, co-authored 5 publications receiving 23 citations.

Papers
More filters
Journal ArticleDOI

Interactions between microbiota, diet/nutrients and immune/inflammatory response in rheumatic diseases: focus on rheumatoid arthritis.

TL;DR: An in-depth analysis on the role of the microbiota in RMDs and on nutritional intervention as an integral part of a multidisciplinary approach is provided.
Journal ArticleDOI

Nutritional status and bone microarchitecture in a cohort of systemic sclerosis patients

TL;DR: In malnourished SSc patients (2015 ESPEN criteria: FFMI<15 kg/m2), an altered bone status significantly correlates with GI involvement, in terms of symptoms being mainly due to intestinal involvement together with the presence of selected serum biomarkers of malnutrition.
Journal ArticleDOI

Lower urinary tract symptoms in systemic sclerosis: a detailed investigation

TL;DR: For the first time urinary tract involvement was found to be significantly higher in SSc patients than in healthy matched controls, and sarcopenia, bone damage and calcinosis appeared significantly correlated with LUTS, suggesting a possible interplay.
Journal ArticleDOI

Body composition and bone status in relation to microvascular damage in systemic sclerosis patients.

TL;DR: SSc patients with most severe microvascular damage show a significantly altered body composition and bone status suggesting a strong link between microv vascular failure and associated muscle/bone sufferance.
Journal ArticleDOI

Microvascular capillaroscopic abnormalities and occurrence of antinuclear autoantibodies in patients with sarcoidosis

TL;DR: In this article , the prevalence of serum anti-nuclear (ANA) and extractable nuclear antigen autoantibodies (ENA) in a cohort of sarcoidosis patients, comparing them with adequate healthy controls (HCs) and with primary Raynaud's phenomenon patients (PRPs).